357 Results (Page 10 of 15)
Malaysia Markets Research Reports
Malaysia Anti-Aging Drugs Market Analysis
Malaysia Anti-Aging Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The Anti-Aging Drugs market is driven by the increasing aging population, advancements in medical research, growing consumer awareness and beauty standards, and the emphasis on preventive healthcare, prompting individuals to seek effective solutions for maintaining a youthful appearance and improving overall well-being. However, the Anti-Aging Drugs market also faces certain restraints. These include stringent regulatory requirements, potential safety concerns, and ethical considerations associated with the use of anti-aging drugs. Additionally, the high cost of some anti-aging drugs may limit their accessibility to a wider population. The Anti-Aging Drugs market is highly competitive, with several key players contributing to its growth and development. Companies such as Allergan, Galderma, Merz Pharma, and Johnson & Johnson are renowned for their expertise in developing and manufacturing anti-aging drugs and treatments.
Malaysia Anti-Venom Market Analysis
Malaysia Anti-Venom Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Purified antibodies are used to prevent snake venom from attaching to tissues and causing severe allergic reactions, blood clotting, muscular injury, or nervous system difficulties. The anti-venom market is being driven by the rising global incidence of snakebites, which is fueling demand for effective snakebite treatment options such as anti-venom products. Anti-venom awareness and education efforts have been critical in emphasising the necessity of anti-venom in snakebite management. Manufacturing and delivery techniques advancements have enhanced the safety, efficacy, and accessibility of anti-venom medications. However, market obstacles include restricted access in rural places, high manufacturing costs, a lack of specificity and efficacy in particular formulations, and safety concerns about potential adverse responses and difficulties during therapy.Some global players in the anti-venom market include CSL Limited, BTG plc, Merck & Co., Inc., Pfizer Inc., Sanofi Pasteur SA, Haffkine Bio-Pharmaceutical Corporation Ltd., Rare Disease Therapeutics, Inc., Instituto Bioclon, S.A. de C.V., and Bharat Serums and Vaccines Limited.
Malaysia Anticoagulants Market Analysis
Malaysia Anticoagulants Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Anticoagulants, commonly known as blood thinners, reduce the risk of blood clots and related consequences by suppressing the clotting mechanisms in the blood. Increased cardiovascular illnesses, an ageing population, greater awareness, technical improvements, advantageous reimbursement policies, and an increase in surgical operations are driving the anticoagulants market. However, there are hazards of bleeding, regulatory requirements, and generic alternatives. The presence of many prominent companies who play a crucial part in developing the industry characterises the global anticoagulants market. Pfizer Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, Sanofi S.A., Novartis AG, Merck & Co., Inc., and Portola Pharmaceuticals, Inc. are among the prominent participants.
Malaysia Antiepileptics Drugs Market Analysis
Malaysia Antiepileptics Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Epilepsy is a chronic neurological disorder characterized by recurrent seizures. The market for antiepileptic drugs is driven by the growing prevalence of epilepsy worldwide and the continuous need for effective and well-tolerated medications. Continuous advances in drug research and development help to bring new and improved antiepileptic treatments to market. These developments result in the creation of pharmaceuticals with improved efficacy, safety profiles, and fewer side effects, which drives market expansion. Some prominent players in the market include UCB Pharma, GlaxoSmithKline plc, Pfizer Inc., Novartis AG, Johnson & Johnson, Sanofi S.A., Eisai Co., Ltd., Sunovion Pharmaceuticals Inc., Cephalon, Inc., and Teva Pharmaceutical Industries Ltd.
Malaysia Antithrombotic Drugs Market Analysis
Malaysia Antithrombotic Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The rising prevalence of cardiovascular disorders, growing geriatric population, developments in medication research, supportive government initiatives and advantageous reimbursement regulations for antithrombotic drugs drive market expansion. The antithrombotic drugs market is dominated by several key players who play a crucial role in driving advancements in the field of cardiovascular medicine. These key players include renowned pharmaceutical companies such as Pfizer Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Sanofi S.A., Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Portola Pharmaceuticals, Inc., AstraZeneca PLC, and Bayer AG.
Malaysia Asthma Drugs Market Analysis
Malaysia Asthma Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The market for asthma drugs is primarily driven by the increasing prevalence of asthma globally, Growing awareness among patients and healthcare providers about the importance of asthma management and the availability of effective treatment options further fuel market growth. Key players in the asthma drugs market include pharmaceutical companies such as GlaxoSmithKline, Roche, AstraZeneca, Novartis, Merck & Co., and Teva Pharmaceutical Industries.
Malaysia Atherosclerosis Drugs Market Analysis
Malaysia Atherosclerosis Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The atherosclerosis drugs market is driven by factors such as the rising prevalence of cardiovascular diseases, advancements in drug development, and growing awareness about early diagnosis and treatment. The key players in the atherosclerosis drugs market include Pfizer Inc., AstraZeneca PLC, Novartis AG, Bristol-Myers Squibb Company, Sanofi S.A., Merck & Co., Inc., Amgen Inc., Eli Lilly and Company, Bayer AG, and GlaxoSmithKline PLC.
Malaysia Atopic Dermatitis Drugs Market Analysis
Malaysia Atopic Dermatitis Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The market for atopic dermatitis drugs is driven by the increasing prevalence of the condition, especially among children, leading to a demand for effective treatments. Some of the prominent players in the market include Pfizer Inc., Sanofi SA, Novartis AG, Regeneron Pharmaceuticals Inc., Galderma S.A., Leo Pharma A/S, AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, and Johnson & Johnson.
Malaysia Autologous Matrix-induced Chondrogenesis Market Analysis
Malaysia Autologous Matrix-induced Chondrogenesis Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The AMIC market is driven by increasing knee injuries and cartilage defects, advancements in regenerative medicine, and the growing geriatric population. However, limited awareness and high costs are restraints. Ongoing research, collaborations, and investments are expected to address restraints and drive further advancements in the AMIC market. Key players globally in AMIC market are Geistlich Pharma AG, Arthrex, Zimmer Biomet Holdings, Smith & Nephew plc, Vericel Corporation, and B. Braun Melsungen AG, among others.
Malaysia Antibacterial (Antibiotics) Drugs Market Analysis
Malaysia Antibacterial (Antibiotics) Drugs Market is at around $81.45 Mn in 2023 and is projected to reach $110.11 Mn in 2030, exhibiting a CAGR of 4.4% during the forecast period. The market is driven by rising rates of infectious diseases, expanding healthcare infrastructure and awareness, and technological advancements. The market is dominated by key players like Duopharma Biotech Bhd, Pharmaniaga Bhd, Ltd., Pfizer Inc., Roche, Novartis AG, GlaxoSmithKline plc, Abbott Laboratories, Johnson & Johnson, Merck & Co., Inc., and Sanofi S.A.
Malaysia Anemia Therapeutics Market Analysis
The Malaysia Anemia Therapeutics Market is anticipated to experience a growth from $24 Mn in 2022 to $48 Mn by 2030, with a CAGR of 9.3% during the forecast period of 2022-2030. The government's deliberate focus on maternal and child health initiatives that address iron deficiency anemia, as well as the creation of business opportunities, treatment demand, and the expansion of healthcare coverage to improve treatment accessibility, are the main factors driving the Malaysian market. The Malaysia Anemia Therapeutics Market encompasses various players across different segments, including Novartis, Roche, Pfizer, Johnson & Johnson, AbbVie, Duopharma, Pharmaniaga, Mead Johnson Malaysia, Baxter International, Fresenius Medical Care, etc, among various others.
Malaysia Cardiovascular Drugs Market Analysis
Malaysia Cardiovascular Drug Market is at around $0.22 Bn in 2022 and is projected to reach $0.30 Bn in 2030, exhibiting a CAGR of 4% during the forecast period. The market is driven by factors such as the aging population, increasing incidence of cardiovascular diseases, and enhanced screening and diagnostics. The market is dominated by key players like Pharmaniaga Berhad, Duopharma Biotech Bhd, B Braun Medical Industries (M) Sdn Bhd, Eschol Pharmaceuticals Sdn Bhd, CCM Pharmaceuticals (SGP), Pfizer Inc., Astra Zeneca, Sanofi, Zydus, and Lupin.
Malaysia Alopecia (Hair Loss) Therapeutics Market Analysis
The Malaysia Alopecia (Hair Loss) Therapeutics Market was valued at US $13 Mn in 2022, and is predicted to grow at (CAGR) of 7.7% from 2023 to 2030, to US $24 Mn by 2030. The primary factors propelling this industry forward include the notable increase in the prevalence of Alopecia (hair loss), technological advancements, and others. The industry is primarily dominated by players such as Johnson & Johnson, Lexington, Sun Pharmaceuticals, Merck, Capillus, Follica Inc., among others
Malaysia Digital Therapeutics Market Analysis
Malaysia Digital Therapeutics Market is at around $10 Mn in 2023 and is projected to reach $57.47 Mn in 2030, exhibiting a CAGR of 27.4 % during the forecast period. Growing chronic illnesses, government programs, and technological developments are driving market growth. The market is dominated by key players like Naluri Hidup, DoctorOnCall, Omada Health Inc., 2Morrow Inc., Livongo Health Inc., WellDoc, Propeller Health, Canary Health, Noom Inc., and Akili Interactive Labs.
Malaysia Allergy Therapeutics Market Analysis
Malaysia Allergy Therapeutics Market was valued at $37 Mn in 2022 and is estimated to reach $62 Mn in 2030, exhibiting a CAGR of 6.6% during the forecast period. The increased incidence of allergic illnesses and associated health issues is driving the need for allergy therapy medications. The major pharmaceutical players that are presently functioning in the market are GlaxoSmithKline, Sanofi, Novartis, Bayer, AstraZeneca, Eisai Co., Takeda Pharmaceutical Company, Pharmaniaga Berhad, Duopharma Biotech Bhd and Reckitt Benckiser.
Malaysia Alcohol Addiction Therapeutics Market Analysis
The Malaysia Alcohol Addiction Therapeutics Market is valued at around $1 Mn in 2022 and is projected to reach $2 Mn by 2030, exhibiting a CAGR of 6.5% during the forecast period. In Malaysia, market growth for alcohol addiction treatment is driven by heightened government involvement, a holistic approach to therapy, and improved accessibility due to economic growth, increased disposable incomes, and expanded insurance coverage and government-funded programs. The key players involved in the research, development, and distribution of Alcohol Addiction Therapeutics in Malaysia are Lundbeck, Roche, AstraZeneca, Alkermes, TEVA Pharmaceuticals, Pfizer, BioCorRx, Otsuka, Pharmaniaga, DuoPharma Biotech etc among others
Malaysia Actinic Keratosis Therapeutic Market Analysis
Malaysia Actinic Keratosis Therapeutic Market is expected to grow at a CAGR of 5.1% over the projected period, from $11 Mn in 2022 to about $16 Mn by 2030. The Actinic Keratosis Therapeutic Market in Malaysia is expanding steadily, propelled by many reasons such as the growing incidence of Actinic Keratosis, heightened consciousness, and enhanced accessibility owing to better healthcare facilities. Actinic Keratosis Therapeutics is being developed and marketed by a number of pharmaceutical firms, including Novartis, Amgen, Johnson & Johnson, Merck, Lumenis, and Pharmaniaga. Etc.
Malaysia Acute Lymphocytic Leukemia (ALL) Therapeutics Market Analysis
The Malaysia Acute Lymphocytic Leukemia (ALL) Therapeutics Market was valued at US $5 Mn in 2022, and is predicted to grow at (CAGR) of 8% from 2023 to 2030, to US $10 Mn by 2030. The key drivers of this industry include a surge in the incidence of acute lymphocytic leukemia cases, technological advancements, increased government funding initiatives, and other factors. The industry is primarily dominated by players such as Pfizer, Novartis, Kotra Pharma, Duopharma among other players
Malaysia Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The Malaysia Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US $ 1.8 Mn in 2022, and is predicted to grow at (CAGR) of 6% from 2023 to 2030, to US $ 2.9 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of autosomal dominant polycystic kidney disease, government initiatives, advanced treatment options and other factors. The industry is primarily dominated by players such as Otsuka, AceLink, Palladio, Reata, Xortx, Regulus among others
Malaysia Age-Related Macular Degeneration Therapeutics Market Analysis
The Malaysia Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $17 Mn in 2022, and is predicted to grow at (CAGR) of 9.10% from 2023 to 2030, to US $35 Mn by 2030. The key drivers of this industry include the rising trend in the prevalence of age-related macular degeneration, evolving healthcare infrastructure, and other factors. The industry is primarily dominated by players such as Regeneron Pharmaceuticals, Novartis, Bayer, Roche, and Genetech, among others
Malaysia Addiction Therapeutics Market Analysis
Malaysia addiction therapeutics market was valued at $16 Mn in 2022 and is estimated to reach $28 Mn in 2030, exhibiting a CAGR of 7.1% during the forecast period. The growing knowledge and understanding of mental health disorders, including substance abuse and addiction, has led to a major growth in the market for addiction therapeutics. The leading pharmaceutical companies in the addiction therapeutics market include Pfizer, GlaxoSmithKline, Novartis, Sanofi, AstraZeneca, Merck, Bayer, Abbott, Johnson & Johnson, and Boehringer Ingelheim.
Malaysia Adult Malignant Glioma Therapeutics Market Analysis
The Malaysia Adult Glioma Therapeutics Market is valued at around $4 Mn in 2022 and is projected to reach $7 Mn by 2030, exhibiting a CAGR of 9.1% during the forecast period. The factors attributed to market growth such as an aging population, improved diagnosis, and heightened awareness, are subsequently driving the demand for therapeutic interventions and are providing new opportunities for the expansion of the glioma therapeutics market. Key players in the Malaysia Adult Malignant Glioma Therapeutics Market include companies like Roche, Novartis, Merck & Co., Pfizer, Bristol-Myers Squibb, Emcure, Sun Pharmaceuticals, AbbVie, Pharmaniaga etc. among others.
Malaysia Vitamin and Minerals Market Analysis
This report presents a strategic analysis of the Malaysia Vitamin and Minerals Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the Malaysia Vitamin and Minerals Market, offering unmatched value, accuracy, and expert insights.
Malaysia Radiotherapy Market Analysis
By 2030, it is anticipated that the Malaysia Radiotherapy Market will reach a value of $xx Mn from $11 Mn in 2022, growing at a CAGR of xx% during 2022-2030. The Radiotherapy Therapeutics Market in Malaysia is dominated by a few domestic players such as Innopharmax Technologies, Hicom-Teck, and VHMED. The radiotherapy market in Malaysia is segmented into different types, technologies, procedures, applications, and end-users. The major risk factors associated with awareness of radiotherapy shortage of skilled staff, government initiatives, and reimbursement policy. The demand for Malaysia Radiotherapy is increasing on account of the rise in cancer cases in the country.
Malaysia Oncology Therapeutics Market Analysis
By 2030, it is anticipated that the Malaysia Oncology Therapeutics Market will reach a value of $565 Mn from $292 Mn in 2022, growing at a CAGR of 8.6% during 2022-30. The Oncology Therapeutics Market in Malaysia is dominated by a few domestic pharmaceutical companies such as Biocon Sdn Bhd, Hovid Berhad, and Pharmaniaga Berhad. The Oncology Therapeutics Market in Malaysia is segmented into different types of cancer and different therapy types. The major risk factors associated with cancer are diet, alcohol, tobacco, air pollution, and physical inactivity. The demand for Malaysia Oncology Therapeutics is increasing on account of the rise in initiatives taken by the Government of the country.